EWTX News and Press, Edgewise Therapeutics Inc. From 02/02/22

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a firesi...

– EDG-5506 was well tolerated with no serious adverse events observed – – Pharmacokinetic (PK) data demonstrated robust target engagement with achievement of muscle concentrations beyond levels predicted to provide meaningful clinical benefit – ...

Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...

– Webcast event to feature EDG-5506 topline results presentation and commentary by a leading neuromuscular disease expert – – Management to provide 2022 Company outlook at the 40 th Annual J.P. Morgan Healthcare Conference on January 10, 2022 – ...

After a sharp decline over the past 30-day period, Edgewise Therapeutics (EWTX +21.8%) and eFFECTOR Therapeutics (EFTR +34.0%), two clinical-stage biopharmaceutical companies that made their trading debuts recently, have recorded notable gains. After a string of intra-day losses, Edgewise (NA...

Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a firesi...

Edgewise Therapeutics (NASDAQ:EWTX): Q3 GAAP EPS of -$0.26 misses by $0.04. Cash and marketable securities of $290M Press Release For further details see: Edgewise Therapeutics EPS misses by $0.04

– Announced positive topline results from the EDG-5506 Phase 1 multiple ascending dose (MAD) study in healthy volunteers (HV) – – Dosed first Becker muscular dystrophy (BMD) patients with EDG-5506 as part of the ongoing Phase 1b trial – ȁ...

Edgewise Therapeutics (NASDAQ:EWTX) posts topline results from the company's early-stage study of EDG-5506. EDG-5506 is an orally administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dys...